1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents
    Meeting Abstract

    Taylor, J.; Coleman, M.; Alvarez, K.; Pichardo, J.; Sen, F.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; Tallman, M. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Chronic lymphocytic leukemia (CLL) transformed into Hodgkin lymphoma (HL): Clinical characteristics and outcomes from a large multi-center collaboration
    Meeting Abstract

    Stephens, D. M.; Boucher, K.; Kander, E.; Parikh, S. A.; Parry, E.; Shadman, M.; Pagel, J. M.; Cooperrider, J.; Rhodes, J.; Mato, A. R.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Long-term follow-up of SWOG S0816: Response-adapted therapy for stage III/IV Hodgkin lymphoma demonstrates limitations of PET-adapted approach
    Meeting Abstract

    Stephens, D. M.; Li, H.; Schoder, H.; Straus, D. J.; Moskowitz, C. H.; Leblanc, M. L.; Rimsza, L. M.; Bartlett, N. L.; Evens, A. M.; LaCasce, A. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Genomic landscape impacts induction outcome with CPX-351 in patients with acute myeloid leukemia
    Meeting Abstract

    Talati, C.; Goldberg, A. D.; Desai, P.; Chan, O.; Famulare, C.; Komrokji, R. S.; Kuykendall, A. T.; Fernandez, H. F.; Deutsch, Y. E.; Padron, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Intestinal enterococcus is a major risk factor for the development of acute GVHD
    Meeting Abstract

    Stein-Thoeringer, C. K.; Peled, J. U.; Gomes, A. L. C.; Lazrak, A.; Docampo, M. D.; Slingerland, A. E.; Nichols, K.; Shono, Y.; Weber, D.; Sung, A. D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Safe and effective use of rivaroxaban for treatment of cancer associated venous thromboembolic disease
    Meeting Abstract

    Soff, G. A.; Sarasohn, D. M. M.; Haegler-Laube, E. S.; Devlin, S. M.; Miao, Y.; Bendheim, G.; Batista, J.; Wills, J.; Mones, J. V.; Wilkins, C.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Pratz, K. W.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Early detection and molecular characterization of therapy-related leukemia in children reveals patterns of disease transformation and guides future surveillance protocols
    Meeting Abstract

    Spitzer, B.; Gundem, G.; Farnoud, N.; Millard, N.; McGovern, E.; Patel, M.; Levine, M.; Medina, J.; Zhou, Y.; Arango Ossa, J. E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Enasidenib is highly active in previously untreated IDH2 mutant AML: Early results from the Beat AML Master Trial
    Meeting Abstract

    Stein, E. M.; Shoben, A.; Borate, U.; Baer, M. R.; Stock, W.; Patel, P. A.; Kovacsovics, T.; Blum, W.; Vergilio, J. A.; Heerema, N. A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): A trial of the ECOG-ACRIN Cancer Research Group (E1912)
    Meeting Abstract

    Shanafelt, T. D.; Wang, V.; Kay, N. E.; Hanson, C. A.; O'Brien, S. M.; Barrientos, J. C.; Erba, H. P.; Stone, R. M.; Litzow, M. R.; Tallman, M. S.
    Blood (2018)

    Fulltext@MSK | Save